Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;61(2):254-263.
doi: 10.1002/mc.23388. Epub 2022 Jan 20.

A review of Plks: Thinking outside the (polo) box

Julianna Korns  1 , Xiaoqi Liu  2 , Vinita Takiar  1   3
Affiliations
Review

A review of Plks: Thinking outside the (polo) box

Julianna Korns et al. Mol Carcinog. 2022 Feb.

Abstract

The polo-like kinase (Plk) family is comprised of five different members (Plk1-5), each with their own distinct functions. Plk family members participate in pivotal cell division processes as well as in non-mitotic roles. Importantly, Plk expression has been correlated with various disease states, including cancer. Multiples therapies, which primarily target Plk1, are currently being investigated alone or in combination with other agents for clinical use in different cancers. As the role of Plks in disease progression becomes more prominent, it is important to outline their functions as cell cycle regulators and more. This review summarizes the structure and both mitotic and non-mitotic functions of each of the five Plk family members, sequentially. Additionally, the proposed mechanisms for how Plks contribute to tumorigenesis and the therapeutics currently under investigation are outlined.

Keywords: Plk1; Polo-like kinase; cancer; radiation; therapeutics.

PubMed Disclaimer

References

REFERENCES

    1. de Cárcer G, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle. 2011;10(14):2255-2262.
    1. Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M. Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol. 2014;15(7):433-452.
    1. Liu X. Targeting polo-like kinases: a promising therapeutic approach for cancer treatment. Transl Oncol. 2015;8(3):185-195.
    1. Klebba JE, Buster DW, McLamarrah TA, Rusan NM, Rogers GC. Autoinhibition and relief mechanism for polo-like kinase 4. Proc Natl Acad Sci USA. 2015;112(7):E657-E666.
    1. Park JE, Soung NK, Johmura Y, et al. Polo-Box Domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci. 2010;67(12):1957-1970.

Publication types

Substances